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Background: Any form of surgery or tissue damage causes release of tissue factor into the circulation. This may
lead to the accelerated consumption of coagulation factors, resulting in severe consumptive coagulopathy. In this
study, we compared the molecular markers involved in coagulation activation during cardiopulmonary bypass
(CPB) between patients who underwent aortic replacement surgery and those who underwent valve surgery.
Methods: This prospective observational study was performed in each 14 patients who underwent aortic
replacement surgery or valve surgery. We evaluated the differences in the levels of fibrinogen, activated factor VII
(FVIIa), thrombin–antithrombin complex (TAT), and soluble fibrin monomer complex (SFMC) during surgery
between these two groups.
Results: The change in fibrinogen levels showed no difference between the groups. The magnitude of increase in
TAT was much larger in patients who underwent aortic replacement surgery than in those who underwent valve
surgery (173.6 vs. 49.4 ng/mL; p = 0.0001). More importantly, the elevation of FVIIa was significantly higher in
patients who underwent aortic replacement (28.5 vs. 19.0 mU/mL; p = 0.0122). The magnitude of increase in SFMC
was also larger in the aortic replacement surgery.
Conclusions: The activation of coagulation during CPB was dramatically higher in the aortic replacement surgery
compared with the valve surgery, probably owing to the activation of the extrinsic coagulation pathway in the
former. This could potentially exacerbate consumptive coagulopathy after CPB termination in patients who
underwent aortic replacement, possibly resulting in massive hemorrhage due to impaired hemostasis.
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Cardiovascular surgery is frequently accompanied by a
bleeding tendency, probably resulting from the impairment
of platelet activation and coagulation caused by cardiopul-
monary bypass (CPB). Aortic replacement surgery using
CPB is frequently complicated by massive hemorrhage that
in turn, is most commonly aggravated by severe hypofibri-
nogenemia due to dilutional coagulopathy. It has been* Correspondence: hideos3150@yahoo.co.jp
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consumptive coagulopathy by continuous thrombin gener-
ation progresses during CPB despite full heparinization of
blood [1, 2]. The activation of the intrinsic coagulation
pathway including the contact phase has been regarded to
be more important in thrombin generation during CPB be-
cause of the direct contact of circulating blood with CPB.
However, the activation of the extrinsic coagulation path-
way by tissue factor (TF) released into the circulation may
be a primary origin of the thrombin generation during
CPB [3]. TF, which is abundantly expressed in the vascular
wall, epicardium, fat, bone, lungs, brain, and muscles [4, 5],le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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tor VII (FVIIa) complex. This complex may then generate
thrombin massively during CPB despite full heparinization
because of the limited thrombin-inhibiting effect and the
subsequent soluble fibrin formation of heparin with anti-
thrombin on the extrinsic coagulation pathway.
In general, aortic replacement surgery is so invasive
that it can potentially cause widespread tissue damage
and increase the release of TF into the circulation. So
far, some studies have shown the activation of extrinsic
coagulation pathway during CPB in coronary artery
bypass grafting (CABG) or valve replacement surgery.
However, the pathology and mechanisms of consumptive
coagulopathy during CPB in aortic replacement surgery
have not been elucidated [6]. In this study, we analyzed
and compared some molecular markers of coagulation
activation {e.g., thrombin-antithrombin complex (TAT),
soluble fibrin monomer complex (SFMC), FVIIa} during
CPB between patients undergoing aortic replacement
surgery and those with valve surgery. Significantly higher
levels of TAT and FVIIa during CPB were observed in
patients who underwent aortic replacement surgery
compared with those who underwent valve surgery. This
observation suggests the accelerated activation of coagu-
lation and consumptive coagulopathy, through the acti-
vation of the extrinsic coagulation pathway in patients
who underwent aortic replacement, possibly resulting in
the impaired hemostasis frequently observed in aortic
replacement surgery.
Methods
The Ethics Committee of the Teikyo University School of
Medicine approved this study. We enrolled patients older
than 20 years who were scheduled to undergo elective aor-
tic replacement surgery or valve replacement surgery, in-
cluding those undergoing surgery combined with CABG.
With a significant level of 5 % and a power of 80 %, a total
of 20 patients were needed to detect a 200 ng/ml differ-
ence in TAT level with a standard deviation of 150 ng/ml.
We estimated that 30 patients should be included in the
trial, 15 patients in each group, because of exclusion cri-
teria and complications during surgery. Written Informed
consent was obtained from all patients. From June 2013
until April 2014, 14 patients who underwent aortic re-
placement surgery and 14 patients who underwent valve
replacement surgery were registered for this prospective
observational study. Patients with congenital bleeding ten-
dency or low platelet count (i.e., <100 × 103/μL) were ex-
cluded. Patients who were administered anticoagulant or
antiplatelet agents were enrolled if these medications were
stopped before surgery. Patients with significant liver and/
or renal dysfunction were excluded as well.
Anesthesia was induced with fentanyl (4–6 μg/kg), mid-
azolam (2–5 mg/body), and rocuronium (0.6–1.0 mg/kg),and then, sevofulrane was used for maintenance. The pa-
tients received artificial respiration, with oxygen concen-
tration at 40 % and end tidal carbon dioxide maintained
at 30–40 mmHg. A peripheral intravenous line, a radial
or a brachial arterial line, a central venous catheter, and
the Swan-Ganz catheter were used to monitor the pa-
tients. Heparin at 300 U/kg was injected before the start
of CPB, and additional heparin was suitably administered
so that the activated clotting time would be more than
400 s throughout the procedure. Heparin was neutralized
with protamine (3 mg/kg) at the end of CPB. A heparin
coating or macromolecule polymer coating was used in
all CPB circuits. Blood from the pleural and pericardial
cavities were recirculated through the reservoir by suc-
tion. The transfusion in each case was decided in charge
by the anesthesiologist because we do not have a stand-
ard protocol.
Blood samples were taken through arterial catheterization
at the induction of anesthesia, at the start of CPB, 1 h from
the start of CPB, and at the end of CPB (i.e., after protam-
ine administration). We measured fibrinogen, SFMC, and
FVIIa by using STA-R Evolution (Diagnostica STAGO,
Asnières sur Seine, France), while TAT was evaluated by
using STACIA (LSI Medience, Tokyo, Japan). As a re-
agent, STA® Fibrinogen (Diagnostica STAGO) was used
for fibrinogen, STACIA CLEAIR TAT (LSI Medience) for
TAT, Auto LIA®FM (Roche Diagnostics K.K., Tokyo,
Japan) for SFMC, and STACLOT® VIIa-rTF (Diagnostica
STAGO) for FVIIa.
We reported the data as the mean ± standard deviation
or as the median (first quartile – third quartile) value.
We used the unpaired t-test or Mann-Whitney U test to
identify differences in the demographic data of patients.
The Mann-Whitney U test was used to determine sig-
nificant differences in the levels of the indicated markers
during CPB between the groups. A p-value of <0.05 was
considered statistically significant. Microsoft Excel Sta-
tistics 2012 was used for the statistical analysis.
Results
The patient characteristics and preoperative laboratory
data showed no significant differences between the groups,
except that the TAT and SFMC levels were significantly
higher in the aortic replacement surgery group (Table 1).
No significant differences were also observed between the
groups except the duration of CPB time, time required for
hemostasis, bleeding and transfusion volumes during sur-
gery (Table 2).
As it has been suggested that the bleeding tendency
and impaired hemostasis during surgery depends upon
the decrease in the plasma level of fibrinogen, we mea-
sured the fibrinogen level during CPB in each case to
evaluate the progression of coagulopathy. Although we ob-
served the tendency for hypofibrinogenemia progression
Table 1 Demographic data of patients
Aortic Replacement Group (n =14) Valve Replacement Group (n = 14) p value
Age (years) 68.4 ± 6.5 70.8 ± 7.3 0.1809
Sex (M/F) 9/5 10/4
Height (cm) 164.3 ± 10.6 158.9 ± 10.3 0.0946
Weight (kg) 64.8 ± 16.8 57.6 ± 11.3 0.0961
BSA (m2) 1.70 ± 0.24 1.59 ± 0.19 0.0892
Cases Ascending Aorta Replacement + AVR 2 MVP 1
AVR 2
Descending Aorta Replacement + CABG 1 AVR + TAP 1
Descending Aorta Replacement 2 AVR +MVP 2
TAR + AVR 1 AVR +MVP + CABG 1
TAR + CABG 3 AVR +MVR + TAP 1
TAR 4 AVR + CABG 5
Ascending Aorta Replacement + AVR + CABG 1 MVR + TAP 1
Fibrinogen (mg/dL) 339 (274–386) 314 (287–356) 0.4762
TAT (ng/mL) 7.7 (4–14.4) 2.1 (1.2–3.2) 0.0009*
SFMC (μg/mL) 20.8 (4.1–109.2) 3.9 (2.4–4.8) 0.0038*
FVIIa (mU/mL) 35.0 (26.3–42.3) 29.5 (21.3–34.8) 0.4616
Hemoglobin (g/dL) 11.6 (10.5–12.9) 11.1 (10.1–13.2) 0.5812
Platelet (×103/mL) 168 (138–194) 169 (133–190) 0.7304
PT-INR 1.17 (1.11–1.24) 1.17 (1.14–1.21) 0.9084
APTT (s) 33.6 (29.8–35.1) 34.0 (29.9–37.0) 0.6458
AVR aortic valve replacement, MVP mitral valve plasty, MVR mitral valve replacement
TAP tricuspid annuloplasty, CABG coronary artery bypass grafting, TAR total arch replacement
*Significant difference between the two groups
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magnitude of decrease in the fibrinogen level during CPB
was not significantly different between the groups (Fig. 1).
We transfused fresh frozen plasma (FFP) before termin-
ation of CPB as a conventional therapy to prevent severe
hypofibrinogenemia. A median of 6 [3–5] units was trans-
fused in 12 patients who underwent aortic replacement,Table 2 Intraoperative and postoperative data
Aortic replacem
Heparin dose for CPB (×103 IU) 18.0 ± 5.2
CPB time (min) 216 (181–232)
Duration of aortic crossclamp (min) 136 (110–182)
Time required for hemostasis 77 (61–147)
Bleeding volume during surgery (mL) 3080 (1888–453
Postoperative blood loss-24 h (mL) 1228 (611–1648
Transfusion of red cell concentrates during surgery (U) 14 (10.5–17.5)
Transfusion of fresh frozen plasma during CPB (U) 6 (4–6)
Transfusion of fresh frozen plasma during surgery (U) 10 (7–20)
Transfusion of platelet concentrates during surgery (U) 20 (20–20)
Postoperative hemoglobin (g/dL) 10.9 (10.1–11.6)
*Significant difference between the two groupsand a median of 0 (0–4) units was transfused in 5 patients
who underwent valve surgery, showing a significant differ-
ence between the groups (p = 0.0012).
To examine the activation of coagulation during sur-
gery, the levels of TAT and FVIIa during CPB were mea-
sured in each case. Although the TAT level at the start
of CPB showed no difference between the groups, itent group (n = 14) Valve replacement group (n = 14) p value
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Fig. 1 Comparison of fibrinogen level between the groups. a: Fibrinogen level at the start of cardiopulmonary bypass (CPB) (1), at 1 h from the
start of CPB (2), and at the end of CPB (3). b: The change of fibrinogen level during CPB. □ (open column): valve surgery; ■ (closed column):
aortic replacement surgery; x: outlier. Data are showed as box and whisker plots (25 and 75 percentiles, outliers). Outliers are showed as cases
with values more than 1.5 times of box lengths from either end of the box. No significant difference in the change of fibrinogen level during
CPB was detected between the groups
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ment group (Fig. 2a). The TAT levels at 1 h from the
start of CPB and at the end of CPB were significantly
higher in the aortic replacement group than those in the
valve surgery group (i.e., 54.4 [40.8–76.9] ng/mL vs. 24.3
[14.9–33.6] ng/mL, p = 0.0051 at 1 h of CPB; 178.8
[144.2–262.5] ng/mL vs. 70.3 [50.6–80.4] ng/mL, p =
0.0001 at the end of CPB). Therefore, a significantly lar-
ger increase in the TAT level during CPB was demon-
strated in the aortic replacement group than that in the
valve surgery group (i.e., 173.6 [125.6–221.5] ng/mL vs.A
Fig. 2 Comparison of thrombin–antithrombin complex (TAT) between the
from the start of CPB (2), and at the end of CPB (3). b: The increase in TAT
replacement surgery; x: outlier; Data are showed as box and whisker plots
values more than 1.5 times of box lengths from either end of the box. #:49.4 [42.7–69.2] ng/mL, p = 0.0001) (Fig. 2b). Mean-
while, both the FVIIa level at the end of CPB and the in-
crease in the FVIIa during CPB were significantly higher
in the aortic replacement group than in the valve surgery
group (i.e., 35 [24.5–43.8] mU/mL vs. 25 [16.5–26.8]
mU/mL, p = 0.0289 at the end of CPB; 28.5 [22.3–36.5]
mU/mL vs. 19.0 [15.3–24.3] mU/mL; p = 0.0122 during
CPB) (Fig. 3). Thus, accelerated coagulation activation
progressed via the extrinsic pathway during CPB in the
aortic replacement surgery group compared with the
valve surgery group.B
groups. a: TAT at the start of cardiopulmonary bypass (CPB) (1), at 1 h
during CPB. □ (open column): valve surgery; ■ (closed column): aortic
(25 and 75 percentiles, outliers). Outliers are showed as cases with
p < 0.05
A B
Fig. 3 Comparison of activated factor VII (FVIIa) between the groups. a: FVIIa at the start of cardiopulmonary bypass (CPB) (1), at 1 h from the
start of CPB (2), and at the end of CPB (3). b: The increase in FVIIa during CPB. □ (open column): valve surgery; ■ (closed column): aortic
replacement surgery; x: outlier; Data are showed as box and whisker plots (25 and 75 percentiles, outliers). Outliers are showed as cases with
values more than 1.5 times of box lengths from either end of the box. #: p < 0.05
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the degree of fibrin generation and consumption of fi-
brinogen, during CPB in each case. We observed signifi-
cantly higher levels of SFMC at all measurement time
points in the aortic replacement group than those in the
valve surgery group (i.e., 15.0 [4.2–42.5] μg/mL vs. 4.1
[3.0–4.8] μg/mL, p = 0.0179 at the start of CPB; 24.5
[3.9–69.1] μg/mL vs. 3.9 [3.5–5.2] μg/mL, p = 0.0344 at
1 h of CPB; 78 [20–122.6] μg/mL vs. 19.8 [13.5–33.6]
μg/mL, p = 0.0216 at the end of CPB) (Fig. 4a). AlthoughA
Fig. 4 Comparison of soluble fibrin monomer complex (SFMC) between th
at 1 h from the start of CPB (2), and at the end of CPB (3). b: The increase
column): aortic replacement surgery; x: outlier; Data are showed as box and
as cases with values more than 1.5 times of box lengths from either end o
during CPB was detected between the groupsthe magnitude of increase in SFMC levels during CPB
was larger in the aortic replacement surgery group, no
significant difference was observed between the groups
(Fig. 4b). To demonstrate the typical accelerated activa-
tion of coagulation in aortic replacement surgery com-
pared with valve surgery, the time courses of fibrinogen,
TAT, and SFMC in the representative case for each
group are shown in Fig. 5. The aortic replacement sur-
gery case showed a dramatic elevation of TAT and
SFMC during CPB. A total of 720 mL of fresh frozenB
e groups. a: SFMC at the start of cardiopulmonary bypass (CPB) (1),
in SFMC during CPB. □ (open column): valve surgery; ■ (closed
whisker plots (25 and 75 percentiles, outliers). Outliers are showed
f the box. #: p < 0.05. No significant difference in the increase in SFMC
ACPB
(1)        (2)       (3)       (4)        (5)       (6)
B
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Fig. 5 Time courses of coagulation markers during surgery in the representative case of each group. a: valve surgery; b: aortic replacement
surgery. ■ (closed column): thrombin–antithrombin complex (ng/mL); □ (open column): soluble fibrin monomer complex (μg/mL). CPB time is
shown by the gray zone. (1) and (7): pre-operation; (2) and (8): pre-CPB; (3) and (9): the start of CPB; (4) and (10): 1 h after the start of CPB; (5)
and (13): the end of CPB; (6) and (15): post-operation; (11): 2 h after the start of CPB; (12): 3 h after the start of CPB; (14): 1 h after the end of CPB
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nogenemia, resulting in diminished reduction of the fi-
brinogen level (Fig. 5b).
Discussion
Cardiovascular surgery using CPB decreases the plasma
concentration of coagulation factors, including fibrino-
gen, primarily by hemodilution with CPB priming and
intravenous fluids [7]. Thoracic aortic replacement sur-
gery is frequently accompanied by massive hemorrhage
due to severe hypofibrinogenemia [8]. A recent report
showed that fibrinogen concentration frequently fell
below 150 mg/dL during CPB in patients who under-
went thoracic aortic repair surgery [8]. We also observed
the tendency for hypofibrinogenemia progression during
CPB in the aortic replacement group, but not in the
valve surgery group (Fig. 1). In order to avoid massive
bleeding due to severe hypofibrinogenemia, we usually
transfuse FFP before termination of CPB in aortic re-
placement surgery. Indeed, significantly more number of
units of FFP was transfused during CPB in the aortic
replacement group, implying that the fibrinogen levels
tended to decrease more during CPB in aortic replace-
ment surgery compared with valve surgery. Although
there were no significant differences in the decrease in
plasma fibrinogen level during CPB between the groups
(Fig. 1), consumptive coagulopathy as well as dilutional
coagulopathy may underlie the development of hypofi-
brinogenemia during CPB in aortic replacement surgery.
There have been several reports of increased coagula-
tion activation markers (e.g., prothrombin fragment 1 + 2,
TAT, fibrinopeptide A, fibrin monomer) during CPB inCABG surgery [9]. In this study, significantly higher TAT
levels during CPB were demonstrated in the aortic
replacement group compared with the valve surgery group
(Fig. 2). The TAT level, which reflects thrombin gener-
ation, was extremely high (i.e., the mean value was
180 ng/mL) at the end of CPB in the aortic replacement
surgery group, as demonstrated by the representative case
(Fig. 5b). This observation indicates the dramatic activa-
tion of coagulation during CPB in aortic replacement sur-
gery because of the TAT level of approximately 40 ng/mL
that is typical of disseminated intravascular coagulation
caused by sepsis or hematological malignancy [10]. The
significant elevation of TAT during CPB in aortic replace-
ment surgery may reflect the CPB time. However, the sig-
nificant difference in TAT levels were already observed at
1 h from the start of CPB in spite of no difference at the
start of CPB between the groups, indicating that the eleva-
tion of TAT did not correlate with the CPB time in each
group. Thus, thrombin generation was strikingly elevated
in the aortic replacement group, independent of the CPB
time. The TAT will reflect the generation of thrombin
through the prothrombinase complex, and this reflects
both extrinsic and intrinsic pathways, more correctly
tenase pathways, with a complexity of positive and nega-
tive feedback pathways and regulatory processes which
are no doubt highly activated during cardiac surgery.
Thrombin generation during CPB might be influenced by
the concentration of heparin, recirculation of blood aspi-
rated from surgical field, and the coating of the extracor-
poreal circuit [11–14]. Previous analyses of thrombin
generation and extrinsic coagulation pathway activation in
suctioned blood from the pericardium and pleural space
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pleural cavity was much higher than that in the plasma.
Thus, TAT elevation during CPB in aortic repair surgery
may be primarily attributed to the recirculation of blood
aspirated from the surgical field.
More importantly, the elevation of FVIIa was also sig-
nificantly higher in the aortic replacement surgery group
compared with the valve surgery group (Fig. 3), indicat-
ing a highly activated extrinsic coagulation pathway in
the latter group despite full heparinization during CPB
in both groups. Although heparin can strongly inhibit
the intrinsic coagulation pathway as well as thrombin,
its inhibitory effect in the extrinsic coagulation pathway
may be relatively weak. Several reports, including the
analysis on time course of intraoperative coagulation
activation in elective CABG surgery [6], have demon-
strated the activation of extrinsic coagulation pathway
during CPB [12]. FVII is activated by TF that is released
from tissues and/or the vascular injury site. As aortic re-
placement surgery is highly invasive, leaked blood into
the pleural cavity in the surgical field may contain high
amounts of TF. This leaked blood is usually recirculated
into the CPB through suction, resulting in the acceler-
ated activation of the FVII in the patients’ blood. Taken
together, the consumptive coagulopathy due to activa-
tion of extrinsic coagulation pathway, may progress con-
tinuously during CPB in aortic replacement surgery. It
has been suggested that reducing thrombin generation
in CPB may result in decreased blood loss and transfu-
sion volumes [12, 14, 17]. Managing the heparin concen-
tration during CPB may contribute to the inhibition of
coagulation activation during CPB [18, 19]. Heparin in-
duces the release of the tissue factor pathway inhibitor
(TFPI), which binds to TF and inactivates it [10], from
vascular endothelial cells [20]. The increase in TFPI in
heparinized blood during CPB [21] may suppress TF/
FVIIa activity to some extent. In any case, consumptive
coagulopathy may progress during CPB in aortic replace-
ment surgery as shown in this study, and thus, it is useful
to evaluate the change of the activation markers of coagu-
lation during CPB.
Although we observed the tendency for larger increases
in the SFMC during CPB in the aortic replacement group
compared with the valve surgery group, the difference was
not significant between the groups (Fig. 4). SFMC includes
soluble fibrin and consists of one-molecule of fibrin
monomer and two-molecules of fibrinogen, fibrin degrad-
ation products, and fibrinogen. This explains how the level
of SFMC is influenced by fibrin degradation products and
fibrinogen, but it does not necessarily reflect an increase
in TAT. Moreover, the half-life of SFMC (i.e., a couple of
hours) is much longer than that of TAT (i.e., less than half
hour). In some cases of thoracic aortic aneurysm,
considerably high levels of SFMC (e.g., >50 μg/mL) weredetected before surgery. The SFMC values were influ-
enced by not only the activation of coagulation pathway
but also fibrinolytic pathway. Moreover, the size of
aneurysm may influence the data of SFMC due to the acti-
vation of fibrinolytic system, resulting in the variable data
of SFMC before surgery. This resulted in no significance
in the SFMC elevation during CPB between the groups.
Thus, elevation of SFMC in aortic replacement surgery
may be influenced not only by intraoperative tissue injury,
but also by preoperative progression of vascular athero-
sclerosis. Sustained elevation of SFMC after CPB suggests
intravascular fibrin or microthrombi formation after CPB,
contributing to organ dysfunction in patients who under-
went aortic replacement surgery [22, 23].
Conclusions
The activation of coagulation cascade as indicated by in-
creases in FVIIa and increased thrombin generation in
TAT during CPB was dramatically higher in the aortic re-
placement surgery group compared with the valve surgery
group. This could potentially exacerbate consumptive co-
agulopathy during and after CPB in patients who under-
went aortic replacement, possibly resulting in perioperative
massive hemorrhage due to impaired hemostasis.
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